Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death
- PMID: 15254145
- DOI: 10.1124/jpet.104.071316
Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death
Abstract
The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) is an important suicide enzyme involved in the defense against O(6)-alkylating mutagens. It also plays a role in the resistance of tumors to anticancer drugs targeting the O(6)-position of guanine, such as temozolomide and fotemustine. Several potent MGMT inhibitors have been developed sensitizing cells to O(6)-alkylating agents. Aimed at targeting MGMT inhibitors to tumor cells, we synthesized MGMT inhibitory compounds conjugated with glucose to improve uptake in tumor cells. Here, we compared O(6)-benzylguanine, O(6)-2-fluoropyridinylmethylguanine (O(6)FPG), O(6)-3-iodobenzylguanine, O(6)-4-bromothenylguanine, and O(6)-5-iodothenylguanine with the corresponding C8-linker beta-d-glucose derivatives. All glucose conjugated inhibitors were 3- to 5-fold less effective than the corresponding nonconjugated drugs as to MGMT inhibition that was measured in cell extracts (in vitro) and cultivated HeLaS3 cells (in vivo). Except for O(6)FPG, IC(50) values of the guanine derivatives applied in vitro and in vivo were correlated. A similar correlation was not obvious for the corresponding glucosides, indicating differences in cellular uptake. C8-alpha-d-glucosides were less effective than beta-glucosides. From the newly developed glucose-conjugated inhibitors tested, O(6)-4-bromothenylguanine-C8-beta-d-glucoside (O(6)BTG-C8-betaGlu) was most potent in inhibiting MGMT both in vitro and in vivo. At a concentration of 0.1 microM, it inhibited cellular MGMT to completion. It was not toxic, even when applied chronically to cells at high dose (up to 20 microM). O(6)BTG-C8-betaGlu strongly potentiated the killing effect of fotemustine and temozolomide, causing reversal from MGMT+ to MGMT- phenotype. Therefore, O(6)BTG-C8-betaGlu seems to be especially suitable for approaching MGMT inhibitor targeting in tumor therapy.
Similar articles
-
The specific role of O6-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy.Future Med Chem. 2018 Aug 1;10(16):1971-1996. doi: 10.4155/fmc-2018-0069. Epub 2018 Jul 13. Future Med Chem. 2018. PMID: 30001630 Review.
-
Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.Curr Med Chem. 2012;19(23):3886-92. doi: 10.2174/092986712802002446. Curr Med Chem. 2012. PMID: 22788764 Review.
-
Synthesis of 131I-labeled glucose-conjugated inhibitors of O6-methylguanine-DNA methyltransferase (MGMT) and comparison with nonconjugated inhibitors as potential tools for in vivo MGMT imaging.J Med Chem. 2006 Jan 12;49(1):263-72. doi: 10.1021/jm050588q. J Med Chem. 2006. PMID: 16392811
-
Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3801-7. Clin Cancer Res. 2003. PMID: 14506174
-
Inactivation of O(6)-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors.Int J Cancer. 2001 Aug 1;93(3):373-9. doi: 10.1002/ijc.1336. Int J Cancer. 2001. PMID: 11433402
Cited by
-
The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer.Cancers (Basel). 2024 Jan 11;16(2):331. doi: 10.3390/cancers16020331. Cancers (Basel). 2024. PMID: 38254819 Free PMC article. Review.
-
Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications.J Clin Med. 2023 Nov 30;12(23):7442. doi: 10.3390/jcm12237442. J Clin Med. 2023. PMID: 38068493 Free PMC article. Review.
-
O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy.Front Oncol. 2020 Jan 17;9:1547. doi: 10.3389/fonc.2019.01547. eCollection 2019. Front Oncol. 2020. PMID: 32010632 Free PMC article. Review.
-
Uptake of glucose-conjugated MGMT inhibitors in cancer cells: role of flippases and type IV P-type ATPases.Sci Rep. 2017 Oct 24;7(1):13925. doi: 10.1038/s41598-017-14129-x. Sci Rep. 2017. PMID: 29066805 Free PMC article.
-
Targeting DNA repair pathways for cancer treatment: what's new?Future Oncol. 2014 May;10(7):1215-37. doi: 10.2217/fon.14.60. Future Oncol. 2014. PMID: 24947262 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials